C4 Therapeutics (CCCC) Equity Ratio (2019 - 2025)
Historic Equity Ratio for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to 0.58.
- C4 Therapeutics' Equity Ratio fell 986.55% to 0.58 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.58, marking a year-over-year decrease of 986.55%. This contributed to the annual value of 0.62 for FY2024, which is 550.17% down from last year.
- Per C4 Therapeutics' latest filing, its Equity Ratio stood at 0.58 for Q3 2025, which was down 986.55% from 0.59 recorded in Q2 2025.
- C4 Therapeutics' Equity Ratio's 5-year high stood at 0.79 during Q2 2021, with a 5-year trough of 0.58 in Q3 2025.
- Over the past 5 years, C4 Therapeutics' median Equity Ratio value was 0.65 (recorded in 2023), while the average stood at 0.67.
- Its Equity Ratio has fluctuated over the past 5 years, first surged by 21537.43% in 2021, then crashed by 1267.99% in 2022.
- C4 Therapeutics' Equity Ratio (Quarter) stood at 0.77 in 2021, then dropped by 12.68% to 0.67 in 2022, then fell by 2.61% to 0.65 in 2023, then decreased by 5.5% to 0.62 in 2024, then decreased by 5.86% to 0.58 in 2025.
- Its Equity Ratio stands at 0.58 for Q3 2025, versus 0.59 for Q2 2025 and 0.61 for Q1 2025.